Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

OraSure Technologies, Inc. OSUR

Healthcare — Medical Instruments & Supplies
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.55
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — 1 — — — 4 — 1 — — — —
Sell — — — — — — — — — — — —
Insider Ownership
6.66%

Capital & Financial Ratios

Market Cap
215.18
Revenue
112.41
Net Income
(49.13)
Free Cash Flow
(48.83)
Net Debt
(160.46)
Current Ratio
8.88
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
2.19
P/B ratio
0.77
Past 5Y EPS Growth
17.20%
This Y EPS Growth
29.79%
Next Y EPS Growth
(22.73%)
Next 5Y EPS Growth
(27.98%)
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 290.41 267.76 199.28 160.58
Receivables 40.17 23.82 22.20 27.36
Inventory 47.61 34.20 31.06 30.07
Other 2.23 3.49 4.15 1.55
386.46 333.22 261.91 222.94
2023 2024 2025 Q'26
Payables 13.15 8.17 6.52 8.40
ST’ Debt — — — —
Other 24.83 22.35 18.38 15.87
39.54 33.48 39.80 25.12
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 27.93 30.64 — —
—
’25 29.93 31.24 27.09 26.76
115.02
’24 54.13 54.34 39.92 37.45
185.83
’23 154.96 85.44 89.19 75.88
405.47
’22 67.71 80.23 116.46 123.08
387.48
’21 58.58 57.61 53.92 63.57
233.67
’20 31.60 29.26 48.01 62.86
171.72
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (13.89) (9.92) — —
—
’25 (19.73) (10.22) (10.07) (9.00)
(49.02)
’24 6.74 7.84 12.68 0.11
27.37
’23 6.00 57.27 36.95 41.37
141.58
’22 (35.82) (9.67) 16.30 (18.01)
(47.20)
’21 (4.39) 0.92 (19.13) (12.78)
(35.38)
’20 2.50 (4.68) 4.38 3.61
5.81
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (14.81) (12.33) — —
—
’25 (19.36) (12.16) (10.89) (10.81)
(53.22)
’24 5.16 6.23 12.54 (0.35)
23.58
’23 4.81 51.53 34.86 40.08
131.28
’22 (84.23) (20.34) 8.76 (15.01)
(110.99)
’21 (15.45) (10.95) (23.70) (33.39)
(83.50)
’20 (0.10) (10.37) (0.82) (14.08)
(23.12)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.32) 0.09 — —
—
’25 (0.21) (0.26) (0.19) (0.27)
(0.94)
’24 (0.05) (0.01) (0.06) (0.14)
(0.26)
’23 0.37 (0.07) 0.15 0.27
0.72
’22 (0.28) (0.26) 0.07 0.21
(0.25)
’21 0.05 (0.02) (0.21) (0.14)
(0.32)
’20 (0.12) (0.16) 0.01 0.03
(0.22)

Target Price Range

High
‡‡‡‡‡
‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 2.62 4.38 3.52 2.08 — — —
Low Price
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.42 8.43 8.45 4.22 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 840 638 501 500 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.46 0.64 0.37 0.23 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 387.48 405.47 185.83 115.02 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 38.31% 42.33% 42.72% 41.90% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (15.67) 56.26 (16.00) (64.59) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.05%) 13.87% (8.61%) (56.15%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (17.13) 53.66 (19.50) (68.73) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 15.31 20.94 10.87 10.19 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.34 5.53 2.50 1.57 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.25) 0.73 (0.26) (0.94) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.65) 1.93 0.37 (0.67) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.88) (0.14) (0.05) (0.06) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.53) 1.79 0.32 (0.72) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.03 5.87 5.51 4.64 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 72.51 73.35 74.43 73.49 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 0.00 11.50 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.90 1.50 1.45 1.55 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.95 1.41 0.65 0.52 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.62 0.79 0.02 (0.16) ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.16) 2.44 0.17 0.34 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (47.20) 141.58 27.37 (49.02) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (63.79) (10.30) (3.80) (4.20) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (110.99) 131.28 23.58 (53.22) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 256.13 346.92 299.74 222.11 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.45 0.23 0.11 0.10 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (107.40) (290.18) (267.65) (199.18) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 364.43 430.67 410.34 340.83 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.79%) 11.58% (4.05%) (15.57%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.39%) 14.54% (12.37%) (31.75%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.60%) 13.50% (4.64%) (18.30%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

OraSure Technologies (OSUR), a diagnostics specialist in oral fluid testing for HIV and other diseases, rode a massive COVID-19 revenue boom from $155 million in 2019 to a peak of $405 million in 2023, driven by at-home test kits, before a brutal 2024 plunge to $186 million (-54% YoY) as pandemic demand evaporated. This cyclical swing exposed over-reliance on temporary tailwinds, with gross margins eroding to 43%, operating losses mounting to -$19 million net income, and efficiency strains evident in headcount cuts from 840 to 501 employees. Yet, the stock trades at deeply depressed levels—near multi-year lows around $3.50—mirroring revenue volatility but hinting at undervaluation amid a rock-solid balance sheet boasting $268 million in net cash and minimal debt.

Valuation metrics scream bargain: PS ratio at 1.4, PB at 0.65 versus book value per share of $5.51, and attractive free cash flow yields, though negative PE reflects ongoing losses. Analyst forecasts predict tepid revenue recovery to $115-129 million by 2027 alongside deepening EPS losses to -$0.72, with ROE struggling below 10% and limited catalysts beyond core diagnostics ramp-up. A recent insider director buy adds a flicker of confidence at trough prices, but projections flag execution risks in a competitive landscape.

This net-cash fortress offers downside protection and potential for steady underperformance rather than explosive growth, positioning OSUR as a speculative hold for value hunters eyeing entries below book value—though conservative portfolios should wait for earnings inflection amid regulatory and stagnation threats.

Read full commentary →

OraSure Technologies, Inc. (OSUR) Latest News

News by impact score

Fine-tune

6 Sep

3 , 7:48 AM
OraSure Technologies returned to profit but faces persistent challenges with growth. Profit recovery signals better financials while elusive growth constrains expansion outlook.

12 Aug

3 transcript www.fool.com, 8:15 PM
OraSure Technologies held its Q2 2026 earnings call to discuss quarterly results, financial performance, and business outlook. Q2 2026 earnings call delivers updates on financials and guidance that moderately influence stock movement and sentiment.

6 Aug

3 transcript app.moby.co, 8:30 AM
OraSure Technologies held its Q2 2026 earnings call covering financial results and business updates. Quarterly earnings call typically provides performance metrics and outlook that can shift near-term investor sentiment.

3 transcript , 1:04 AM
OraSure Technologies reported 9% revenue growth during its Q2 2026 earnings call. Revenue increase from earnings call signals moderate positive effect on financial results and near-term stock sentiment.

3 www.marketbeat.com, 12:03 AM
OraSure Technologies discussed Q2 financial results, product updates and outlook during its earnings call. Q2 earnings call updates typically offer moderate insight into operations and outlook without major strategic shifts.

5 Aug

3 , 4:05 PM
OraSure Technologies, Inc. (OSUR) announced its second quarter 2026 financial results. Quarterly earnings releases typically drive short-term stock moves and moderate shifts in market views of financial health.

21 Jul

4 , 4:30 PM
OraSure Technologies receives Emergency Use Authorization for its second-generation Ebola test. Emergency Use Authorization for second-generation Ebola test enables immediate commercialization and expands OraSure revenue opportunities in diagnostics.

11 Jun

4 , 8:00 AM
OraSure Technologies, Inc. obtained FDA clearance expanding patient-friendly access to sexually transmitted infection testing. FDA clearance directly expands OraSure's STI testing market reach and revenue potential.

7 May

3 app.moby.co, 8:30 AM
OraSure Technologies, Inc. released Q1 2026 earnings call summary highlighting financial results, operational updates, and future guidance. Quarterly earnings summaries provide key financial metrics and outlook that moderately influence stock performance and investor sentiment.

6 May

4 transcript www.fool.com, 6:47 PM
OraSure Technologies (OSUR) released Q1 2026 earnings call transcript detailing financial results, guidance, and management commentary. Q1 2026 earnings transcript reveals financial performance and forward guidance directly impacting OSUR's valuation and market trajectory.

4 GlobeNewswire, 4:05 PM
OraSure Technologies announced first quarter 2026 financial results, reporting revenue, earnings per share, and operational updates. Quarterly earnings releases deliver key financial metrics that significantly impact stock price and investor perceptions of future performance.

3 www.marketbeat.com, 11:06 PM
OraSure Technologies released Q1 earnings call highlights detailing financial performance, strategic updates, and forward guidance. Q1 earnings highlights address financial results and outlook with moderate influence on investor sentiment and stock trajectory.

16 Apr

4 Insider Monkey, 3:27 AM
OraSure Technologies (OSUR) faces intensifying pressure to sell, thrusting the company back into investor spotlight amid strategic sale discussions. Building sale pressure signals potential acquisition or merger, poised to significantly reshape OSUR's strategic direction and market valuation.

17 Mar

4 GlobeNewswire, 4:52 PM
OraSure Technologies highlights significant operational progress and value creation initiatives in response to a letter from Altai Capital. Operational progress and value creation initiatives address activist investor concerns, likely influencing strategic direction and market sentiment.

4 Business Wire, 9:15 AM
Altai Capital Management issued a letter to OraSure Technologies' board outlining a five-pillar case for change in response to the company's significant and continued underperformance. Activist investor pressure via a detailed letter demanding board changes due to underperformance could drive major strategic shifts and boost investor sentiment.

26 Feb

4 app.moby.co, 8:30 AM
OraSure Technologies, Inc. released Q4 2025 earnings call summary detailing financial results, operational updates, and forward guidance. Q4 earnings call summary discloses financial performance and strategic outlook, significantly influencing investor sentiment and stock trajectory.

4 www.marketbeat.com, 2:11 AM
OraSure Technologies released Q4 earnings call highlights, covering financial results, revenue growth, product updates, and future outlook amid shifting market dynamics. Q4 earnings highlights detail financial performance, strategic initiatives, and guidance that significantly shape investor expectations and stock trajectory.

4 GuruFocus.com, 12:02 AM
OraSure Technologies Inc (OSUR) Q4 2025 earnings call highlights revenue exceeding expectations amid strong performance. Revenue beating expectations boosts OSUR's financial results and investor sentiment significantly.

25 Feb

4 Associated Press Finance, 5:39 PM
OraSure Technologies, Inc. (OSUR) released its Q4 earnings snapshot. Q4 earnings snapshots directly affect financial performance metrics and investor sentiment for OSUR.

4 , 4:05 PM
OraSure Technologies, Inc. (OSUR) announced its fourth quarter 2025 financial results. Q4 financial results announcement typically drives significant shifts in stock price and investor outlook for OSUR.

10 Feb

4 GlobeNewswire, 8:05 AM
OraSure Technologies, Inc. is set to launch the OraQuick™ HIV Self-Test in Canada, expanding access to at-home testing for HIV. This initiative aims to enhance early detection and treatment of HIV, aligning with public health goals. The self-test will be available at various retail locations and online, marking a significant step in the company's efforts to address HIV testing accessibility. The launch of the OraQuick™ HIV Self-Test in Canada represents a significant strategic move that could enhance market presence and investor sentiment.

15 Jan

3 GlobeNewswireSimply Wall St.MT NewswiresSimply Wall St., 1:00 PM
OraSure Technologies, Inc. has confirmed the receipt of director nominations from Altai Capital, a significant move that may influence the company's governance and strategic direction. This development highlights ongoing shareholder engagement and potential shifts in board composition, which could impact future decision-making processes. Changes in board composition can moderately influence company strategy and investor sentiment.

3 Business WireSimply Wall St.MT NewswiresSimply Wall St.MT NewswiresMT NewswiresMT NewswiresBenzinga, 8:30 AM
Altai Capital Management has nominated two candidates for election to the board of directors of OraSure Technologies, Inc. (OSUR). This move is part of Altai's efforts to influence the company's governance and strategic direction, aiming to enhance shareholder value. The nominations come amid ongoing discussions about the company's performance and future prospects. Board nominations can influence governance and strategic direction, potentially affecting the company's performance.

6 Jan

4 Zacks, 11:39 AM
OraSure Technologies, Inc. has submitted a request for FDA review of its new molecular self-test and the Colli-Pee device, which is designed for urine collection. This move aims to enhance the company's product offerings in the diagnostics market, potentially improving accessibility and convenience for users. The FDA's evaluation will be crucial in determining the future availability and commercial success of these products. The FDA review of new diagnostic products could significantly impact OraSure's market position and investor sentiment.

5 Jan

4 GlobeNewswire, 8:00 AM
OraSure Technologies, Inc. has submitted its CT/NG molecular self-test and the Colli-Pee™ urine collection device for FDA review, aiming to enhance its product offerings in the diagnostics market. These submissions are part of the company's strategy to expand its portfolio and improve accessibility to testing solutions. The FDA review of new diagnostic products could significantly impact OraSure's market position and future revenue streams.

17 Dec

3 GlobeNewswire, 1:23 PM
OraSure Technologies, Inc. announced that Altai Capital intends to nominate candidates for the company's board of directors. The company is evaluating the nomination and will respond appropriately. OraSure emphasizes its commitment to enhancing shareholder value and maintaining effective governance. Board nominations can influence governance and strategic direction, impacting investor sentiment and company performance.

3 Business Wire, 8:00 AM
Altai Capital Management has announced its intention to nominate two candidates for election to the board of directors of OraSure Technologies, Inc. The move is part of Altai's efforts to influence the company's governance and strategic direction, aiming to enhance shareholder value. Board nominations can influence company strategy and governance, potentially affecting financial performance.

16 Nov

3 Simply Wall St., 7:32 AM
Insider buying at OraSure Technologies, Inc. has reached a total of $761,000, indicating strong confidence from executives in the company's future performance. This significant investment by insiders may reflect positive expectations regarding the company's strategic direction and market position. Insider buying suggests confidence in the company's future, which may moderately influence market sentiment and performance.

6 Nov

3 transcript GuruFocus.com, 12:07 AM
OraSure Technologies, Inc. (OSUR) reported its Q3 2025 earnings, highlighting challenges in the market, including competitive pressures and regulatory hurdles. The company is focusing on strategic initiatives to enhance product offerings and improve operational efficiency. Despite these challenges, management expressed optimism about future growth opportunities and ongoing investments in innovation. The earnings call emphasized the importance of adapting to market dynamics while maintaining a strong financial position. Moderate challenges and strategic initiatives are expected to influence financial performance and competitive positioning.

5 Nov

3 ZacksGuruFocus.comAssociated Press FinanceSimply Wall St.ZacksZacks, 6:50 PM
OraSure Technologies, Inc. (OSUR) reported a loss in Q3, falling short of revenue estimates. The company's financial performance has raised concerns among investors, as it struggles to meet market expectations. This disappointing report may impact investor sentiment and the company's future outlook. The Q3 loss and revenue shortfall may moderately influence investor sentiment and financial performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us